Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( (OKYO) ).
On February 12, 2026, OKYO Pharma announced plans for an underwritten public offering of its ordinary shares, with all shares to be issued and sold by the company. The company also expects to grant the underwriter a 30-day option to buy up to an additional 15% of the shares sold at the public offering price, subject to market conditions and final terms.
Piper Sandler & Co. has been appointed sole book-running manager for the offering, which is being made under OKYO’s recently declared-effective shelf registration statement on Form F-3. OKYO intends to use the net proceeds primarily to fund clinical development of its product candidates, including advancing urcosimod, as well as for general corporate purposes and working capital, potentially strengthening its financial position as it moves into later-stage trials in ocular indications.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market, focused on developing innovative therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s flagship drug candidate, urcosimod, recently completed a successful phase 2 trial in neuropathic corneal pain, with a roughly 150-patient Phase 2b/3 multiple-dose study planned to begin in the first half of this year.
Average Trading Volume: 202,066
Technical Sentiment Signal: Sell
Current Market Cap: $78.61M
For a thorough assessment of OKYO stock, go to TipRanks’ Stock Analysis page.